When was Kedalion Thera founded?

Kedalion Thera was founded in 2015 and raised its 1st funding round 3 years after it was founded.

Where is Kedalion Thera located?

Kedalion Thera is headquartered in Menlo Park, United States.

How many employees does Kedalion Thera have?

As of Jul 01, 2024, the latest employee count at Kedalion Thera is 10.

Is Kedalion Thera a funded company?

Kedalion Thera is a funded company, having raised a total of $5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 06, 2018.

When was the latest funding round of Kedalion Thera?

Kedalion Thera's latest funding was a $***** Series B round on Nov 15, 2021, with participation from 1 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $603M in funding in 2026 to date.

Where does Kedalion Thera rank among its competitors?

Kedalion Thera ranks 5th amongst 34 active competitors, of which 11 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Eyenovia, which secured $50M in Jun, 2025.

Who are the top competitors of Kedalion Thera?

Kedalion Thera's top competitors include Eyenovia, PolyActiva and Re-Vana Therapeutics. Among them, Eyenovia secured the most recent funding round in June, 2025.

Kedalion Thera - 2026 Company Profile, Team, Funding & Competitors

Kedalion Thera is an acquired company based in Menlo Park (United States), founded in 2015 by Mark Blumenkranz. It operates as a Provider of drug delivery system for eye diseases. Kedalion Thera has raised $5M in funding from Novartis and Lagunita Biosciences. The company has 34 active competitors, including 11 funded and 4 that have exited. Its top competitors include companies like Eyenovia, PolyActiva and Re-Vana Therapeutics.

Company Details

Provider of drug delivery system for eye diseases. The company's AcuStream technology is for delivering topical drugs to the eye. The company claims that the system will reduce the rate of overdose, administration error, contamination, and discontinuation rate.

Website: kedalionthera.com
Email ID: *****@kedalionthera.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2015

Location

Menlo Park, United States

Stage

Acquired

Total Funding

$5M in 2 rounds

Latest Funding Round

Series B, Nov 15, 2021, $*****

Investors

Novartis & 1 more

Ranked

5^th among 34 active competitors

Employee Count

10 as on Jul 01, 2024

Similar Companies

Eyenovia & 36 more

Exit Details

Acquired by Novartis (Jul 01, 2022)

View Kedalion Thera's full profile

Kedalion Thera got acquired by Novartis on Jul 01, 2022.

Click here to take a look at Kedalion Thera's acquisition in detail

Kedalion Thera has raised a total funding of $5M over 2 rounds. Its first funding round was on Aug 06, 2018. Its latest funding round was a Series B round on Nov 15, 2021 for $*****. 1 investor participated in its latest round. Kedalion Thera has 2 institutional investors.

Here is the list of recent funding rounds of Kedalion Thera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 15, 2021	4754878	Series B	1730287	8907632	3464027	4751021
Aug 06, 2018	4682047	Series A	2457957	7044394	Lagunita Biosciences	4717358

Access funding benchmarks and valuations. Sign up today!

View details of Kedalion Thera's funding rounds and investors

The founders of Kedalion Thera is Mark Blumenkranz.

Here are the details of Kedalion Thera's key team members:

Mark Blumenkranz: Co-Founder & Chairman of Kedalion Thera.

View details of Kedalion Thera's Founder profiles and Board Members

Kedalion Thera's employee count trend

Kedalion Thera has 10 employees as of Jul 24. Here is Kedalion Thera's employee count trend over the years:

Uncover Kedalion Thera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kedalion Thera include Eyenovia, PolyActiva and Re-Vana Therapeutics. Here is the list of Top 10 competitors of Kedalion Thera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eyenovia 2014, New York City (United States), Public	Developer of microdose therapies for treating myopia	$10M	Senju Pharmaceutical, Eshelman Ventures & 3 others	57/100
2nd	PolyActiva 2010, Melbourne (Australia), Series C	Drug delivery platform	$46.7M	National Reconstruction Fund, Brandon Capital ... & 2 others	56/100
3rd	Re-Vana Therapeutics 2015, Belfast (United Kingdom), Series A	Developer of drug delivery platform forophthalmic diseases	$16.7M	Visionary Ventures, Exsight Ventures & 11 others	50/100
4th	Everads Therapy 2017, Tel Aviv (Israel), Funding Raised	Drug & a cell targeting system for posterior segment eye diseases	-	EIC Fund, RAD BioMed & 1 others	45/100
5th	Kedalion Thera 2015, Menlo Park (United States), Acquired	Provider of drug delivery system for eye diseases	$5M	Novartis, Lagunita Biosciences	44/100
6th	LayerBio 2013, Boston (United States), Acquired	Developing innovative ophthalmic therapies, including sustained-release drug delivery for cataract surgery	$205K	National Science Foundation, C2I Accelerator ... & 1 others	42/100
7th	MgShell 2019, Milano (Italy), Series A	Developer of an intraocular device for drug delivery	$1.83M	Club degli Investitori, Capital Cell & 6 others	40/100
8th	MediPrint 2001, San Diego (United States), Series A	Developer of technology for ocular drug delivery	$11.4M	-	36/100
9th	Amorphex 2010, Andover (United States), Seed	Developer of drug delivery device for ophthalmic diseases	$265K	-	34/100
10th	Opharmic 2016, Hong Kong (China), Funding Raised	Developer of non-invasive ocular drug delivery system	-	MedTech Innovator, Pentepebble	34/100